Related stocks:
Leading stocks (600630)
And related reasons: Shanghai SASAC’s holding company Shanghai Shuanglong High-tech Development Co., Ltd. has modern textile manufacturing Base, the company holds 94 shares and is mainly engaged in the development of biological products and new technological materials.
Main business: brand sales and ethnic trade, clothing and home textiles
Theme: New retail Ebola concept local state-owned assets reform
Company profile: Shanghai leader (Group) Co., Ltd. is mainly engaged in brand sales and international trade. Its main products include knitted underwear, home series, casual series, underwear, bras, sheets, quilt covers, pillowcases, back covers, quilts, blankets, towels, shirts, casual pants, T-shirts, sweaters, jackets, down jackets, coats, etc.
Shuanglu Pharmaceutical (002038)
And reasons for selection: It has a leading position in the treatment of tumors, liver and kidney diseases, diabetes, and cardiovascular and cerebrovascular diseases. The company is a Chinese genetic engineering company. A key enterprise in the pharmaceutical industry.
Main business: research, development, production and operation of genetic engineering and related drugs.
Theme concept: Biomedical gene sequencing heparin
Company profile: R&D; P management of R&D and production, changes in the layout of Jinduo Tuanzhibingnuo, R&D; R&D of major products And production includes Beijing Shuanglu Pharmaceutical Co., Ltd., which mainly focuses on genetic engineering and related drugs, such as recombinant human basic fibroblast growth factor, temozolomide, arsenic trioxide, lenalidomide, compound auxiliary recombinant human granulocyte stimulating factor, Recombinant human interleukin 2, recombinant human interleukin 11 docetaxel, adefovir dipivoxil dropping pills, etc. Related to tumors, liver disease, cardiovascular and cerebrovascular diseases. Enzymes, thymosin, Genhua Fangcai sodium, ampicillin dispersible tablets, the first batch of "Hundred Innovative Enterprises" of Ximi Xiangyuan, Beijing Biomedical Industry Leap-forward Development Project (G20 Project), Zhongguancun National Competition Area selected as a key high-tech in the National Torch Program Technology enterprise, Zhongguancun Science and Technology Park Haidian Pharmaceutical Independent Innovation Demonstration Zone's first batch of "Key Cultivation Enterprises for the 100,000 Project".
Qian Pharmacy (002550)
And reasons for selection: The COVID-19 nucleic acid detection kit of Jinghongsheng Branch, a well-known polysaccharide and protease manufacturer in the domestic biochemical pharmaceutical industry, has obtained CE certification. .
Main business: research and development; d. Lyophilized powder, freeze-dried powder injection (including anti-tumor drugs), small-volume injection (non-terminal sterilization), tablets, hard Production and sales of capsules, granules, and APIs.
Theme concept: Consistency evaluation of generic biomedical heparin
Company profile: Changzhou Hongqian Biochemical Pharmaceutical Co., Ltd. is mainly engaged in freeze-dried powder and frozen products within the scope of the drug production license. R&D, production and sales of dry powder injections (including anti-tumor drugs), small volume injections (non-terminal sterilization), tablets, hard capsules, granules and APIs. The company has 46 product specifications, including tablets, hard capsules, freeze-dried powder and freeze-dried powder injections, small-volume injections and APIs. The main products include two series: biochemical drugs, active enzymes and polysaccharides. Among them, the active enzymes mainly include pancreatic kallikreinogenase series, compound digestive enzyme capsules, elastase and 1-paraginase series; polysaccharide varieties mainly include heparin sodium and low molecular weight heparin series varieties. As an expert in the field of animal-derived enzyme preparations, the main product Yikai brand has been rated as a national well-known trademark.
China Resources Sanjiu (000999)
And reasons for selection: OTC company ranks first overall and owns the well-known pharmaceutical brand ‘999’. The company's main products include: 999 Ganmao Ling, cephalosporins for injection, etc.
Main business: research and development; d. production and sales of pharmaceutical products and related health services.
Theme Concept: Reform of State-owned Assets of Central SOEs in Traditional Chinese Medicine for Influenza
Company Profile: China Resources Sanjiu Pharmaceutical Co., Ltd. is mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. The main products include 999 Ganmaoling, 999 Piyanping, Shenfu Injection, cephalosporins for injection, non-fried Chinese medicine, Sanjiu Weitai Granules, Zhengtian Pills, etc.
"999" main brand en
and reasons for selection: It has realized the localization of microbial detection and control technology and has become a leading enterprise in the industry. The company's microbial detection technology series and other products are of great value in the field of microbial-related drug quality inspection.
Main business: research and development; d. Manufacturing and sales of microbial detection and control technology system products and organic analysis instruments and other pharmaceutical equipment.
Theme concept: Food safety and biosafety testing of COVID-19
Company profile: Zhejiang Tailin Biotechnology Co., Ltd.’s main business is microbial detection and control technology system products, organic R&D, manufacturing and sales of pharmaceutical equipment such as analytical instruments. The company's main products include various consumables, instruments and equipment in microbial detection technology series, separation technology series and sterilization technology series. The company won the "First Prize for Advanced Collective Award for Technological Innovation in China's Pharmaceutical Equipment Industry" issued by the China Pharmaceutical Equipment Industry Association.
Wanfu Biological (300482)
And reasons for selection: An excellent supplier of rapid detection products in the in vitro diagnostic industry. The company's colloidal gold COVID-19 antibody detection reagent won the bid for joint procurement in Beijing, Tianjin and Hebei.
Main business: research and development; manufacturing, sales and service of rapid diagnostic reagents and supporting instruments.
Theme concept: Biomedical gene sequencing hepatitis concept
Company profile: Guangzhou Wanzi Biotechnology Co., Ltd. specializes in the research and development, manufacturing, marketing and service of rapid diagnostic reagents and supporting instruments. It is one of the leading POCT companies in China. Product lines in major testing fields such as cardiovascular and cerebrovascular, inflammation, tumors, infectious diseases, drug testing (drug abuse), and eugenics. In 2019, the company obtained the MDSAP certificate for the first time, proving that the company's quality system complies with the IS013485:2016 standard and the regulatory requirements of the Australian FDA, HC, TGA, and Brazilian ANMISA.
China Resources Crane (600062)
And reasons for selection: the country’s largest infusion supply base and the country’s leading fully synthetic antibacterial drug production base. The company has long had production numbers for Ebola inhibitor drugs and also produces raw materials.
It is more likely to choose a designated location designated by the State Food and Drug Administration to produce Ebola inhibitor indicators
Main business: three major businesses: chronic disease business, specialist business and infusion business.
Theme Concept: Artemisinin, Influenza, Heparin, State-owned Assets Reform of Central Enterprises
Company Profile: Huajian Hanfei Pharmaceutical Co., Ltd. is a company whose main business is chronic disease business, specialist business and field The three major businesses of rush business. The main products include Compound Lihe Xueping Ammonia Tea Paiding Tablets (No. 0), Sodium Cythiocholeide Tablets (Xibai Note), Amlodipine Tablets (Lowderda), Pingjiu Super Slow Process Tablets (High Su), Glitaline Zhongqiang Chao Tablets Chu Shiping) soft bag (containing straight soft, inner-sealed polypropylene end infusion.
Nine out of ten people who speculate in stocks do not know how to "select bones, time, and risk control". This is the fundamental reason why you lose money by speculating on bones.
Lao Xiao solemnly promises: friendly exchanges! Shareholders with good moral character, high quality and love to learn are welcome to discuss with each other!
(1 )Learn to look at the market trend and choose strong sectors
(2) Learn to distinguish short-term votes from the main players of hot money and trend votes from the main institutions
(3) Learn to eat meat with the main players , advance and retreat with the main force
(4) Learn to take profits, stop losses and position management, and say goodbye to heavy losses
(5) Learn to formulate and implement trading plans, Summarize experience and insights
(6) Share market trends, sector evolution and bull-catching logic every day, and create the most valuable content.
Choose the strongest stocks and become the top expert. , encourage you!
Exclusive articles and call auction stocks are updated on time at 9:30 every day before the market opens, and exclusive review articles are updated from time to time after the market closes!
Another mention There was so much bad news over the weekend that the market sentiment was generally pessimistic, and the more we faced this situation, the more we had to stay sober and calm and face it calmly. It is not appropriate to continue to make negative and pessimistic remarks now, because it will only be in vain. It increases anxiety but does nothing to help.
This week, the most important thing may be to control the position, don’t be too reckless, and remember to squeeze out some space when the position is full. During this period, unknown hepatitis suddenly broke out in foreign countries and attacked children, causing people to panic. Therefore, the concept of hepatitis has the opportunity to become a hype point for funds, so you can take a look.
In addition, new stocks have frequently broken prices recently, so that investors’ enthusiasm for new stocks has dropped sharply, and their confidence has been seriously frustrated. In order to "don't leave, folks", this week's new stocks and sub-new stocks may put on a good show, and you can watch the show. There is also agriculture. Food is the most important thing for the people. There are expectations and it has just been adjusted so that it will not be abandoned.
In fact, it can be seen from some trends over the weekend that the current market situation is actually very tense; of course, the tense points may be different from ours. However, when their emotions are excessively vented, I believe they cannot ignore it completely. After all, the impact will not be good.
In short, be careful. The most important thing before May Day is defense. After all, if you have a bad week, it will also affect your mood during the May Day holiday. Related Q&A: Leading pharmaceutical stocks for the treatment of liver diseases
Stock: Furui Holdings.
Fu Rui Shares (300049): a leader in liver diseases. This company has a medical service platform for the entire industry chain of liver disease. Its main diagnostic products are the Fibroscan series of liver fibrosis diagnostic instruments, which are the world's first non-invasive liver fibrosis detection equipment; it holds 13.01 shares of French Median, which is a high-end tumor imaging software Provider; medical device revenue in 2017 was 494 million, accounting for 58.09%.
The company’s main businesses are pharmaceutical production and sales, diagnostic equipment R&D and sales, and O2O severe vertical chronic liver disease management medical services.
Features of Furui Company:
The company is a pharmaceutical manufacturing and medical service provider focusing on the field of liver diseases. Its main business is mainly divided into three aspects: Compound Turtle A and Soft Liver The production and sales of pharmaceuticals with tablets as the leading products; the production and sales of the world's exclusive and innovative "Fibroscan" series of medical devices for quantitative detection of liver stiffness and fatty changes; a vertically integrated chronic liver ptosis management platform is being built to provide relevant Medical services, and agency sales of related drugs.